PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1462909
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1462909
Exosome Diagnostic and Therapeutic Market size was valued at USD 476.01 Million in 2023, expanding at a CAGR of 28.5% from 2024 to 2032.
The membrane-bound vesicle known as an exosome is produced in the extracellular space of eukaryotic cells. Applications of exosomes include immunological responses, viral pathogenicity, cardiovascular disease, diseases of the central nervous system, and the advancement of cancer. Exosomes efficiently transport biomolecules such as proteins, metabolites, and nucleic acids into target cells to modify their biological response. With the capacity to target specific targets, exosomes are designed to carry a variety of therapeutic payloads, such as immune modulators, chemotherapeutic drugs, antisense oligonucleotides, and short interfering RNAs. Liquid biopsy based on exosome vesicles has the potential to be employed in the diagnosis and prognostication of cancer and other diseases.
Exosome Diagnostic and Therapeutic Market- Market Dynamics
Increasing prevalence of cardiovascular disease to propel market demand
The market for exosome diagnostic and therapeutic products is expanding due to the increased incidence of cardiovascular disorders. This is ascribed to the advancement of long-lasting, technologically sophisticated equipment. Among the main causes of cardiovascular disease are a poor diet, tobacco use, and a lack of physical activity, all of which increase blood pressure and blood sugar levels, leading to overweight and obesity. Heart attacks and strokes account for four out of every five cardiovascular fatalities, according to the WHO, with one-third of these deaths occurring prematurely in those under the age of 70. Consequently, during the projected period, the Exosome Diagnostic and Therapeutic Market is expected to grow at a faster rate.
Exosome Diagnostic and Therapeutic Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 28.5% over the forecast period (2024-2032)
Based on product segmentation, the Reagent segment is expected to dominate the market over the forecast period
Based on the application segmentation, the Diagnostic segment is expected to lead the market growth during the forecast period
Based on end user segmentation, the Cancer Institute segment is expected to hold the largest market share over the projected period
Based on region, North America was the leading revenue generator in 2023
The Global Exosome Diagnostic and Therapeutic Market is segmented based on Product, Application, End User, and Region.
Based on the product, the market is categorized into Instrument, Reagent and Software. The Reagent segment is expected to dominate the market over the forecast period due to the rise in R&D efforts for diagnostic purposes as well as the growing necessity for molecular diagnosis.
Based on the application, the market is divided into Diagnostic and Therapeutic. The Diagnostic segment is expected to lead the market growth during the forecast period due to the rise in the prevalence of chronic illnesses and the increased need for early diagnosis.
Based on the end user, the industry is divided into Cancer Institute, Hospital, Diagnostic Center and Others. The Cancer Institute segment is expected to hold the largest market share over the projected period. The segment growth is attributable to increase in the prevalence of cancer, increase in the number of hospitals, and spike in government programs for the development of healthcare infrastructure.
Exosome Diagnostic and Therapeutic Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to hold the majority of market share during the forecast period. The regional market expansion is attributed to the growing prevalence of chronic disease such as cancer, cardiovascular, diabetes and others. For instance, in 2022, there will be an anticipated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States, according to the American Cancer Society's estimates. Thus, the aforementioned stats drives the market growth.
The key players in the market are NX Pharmagen, Inc., Capricor Therapeutics, Inc., System Biosciences, Inc., NanoSomix, Inc, Thermo Fisher Scientific, Inc., Exiqon A/S, Aethlon Medical, Inc., Malvern Instruments Ltd, Sistemic Ltd and Exosome Diagnostic, Inc. These players adopted various strategies such as product launch, expansion, investment, collaboration, and others to obtain the maximum market share of the market.
In January 2024, the MassivEVTM EV Purification Column PS and MassivEVTM Purification Buffer Set, products made for high-purity and high-efficiency mass purification of extracellular vesicles (EVs) to promote exosome research, were recently introduced by FUJIFILM Wako Pure Chemical Corporation.
GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
NX Pharmagen, Inc.
Capricor Therapeutics, Inc.
System Biosciences, Inc.
NanoSomix, Inc
Thermo Fisher Scientific, Inc.
Exiqon A/S
Aethlon Medical, Inc.
Malvern Instruments Ltd
Sistemic Ltd
Exosome Diagnostic, Inc.